How have NURO shares performed in 2024?

NeuroMetrix's stock was trading at $3.60 at the beginning of the year. Since then, NURO stock has increased by 16.4% and is now trading at $4.19. View the best growth stocks for 2024 here .

Are investors shorting NeuroMetrix?

NeuroMetrix saw a decrease in short interest in March. As of March 31st, there was short interest totaling 11,300 shares, a decrease of 51.3% from the March 15th total of 23,200 shares. Based on an average daily trading volume, of 44,800 shares, the short-interest ratio is currently 0.3 days. Approximately 0.8% of the shares of the stock are sold short. View NeuroMetrix's Short Interest .

When is NeuroMetrix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our NURO earnings forecast .

How were NeuroMetrix's earnings last quarter?

NeuroMetrix, Inc. (NASDAQ:NURO) announced its quarterly earnings results on Thursday, February, 22nd. The medical device company reported ($1.43) earnings per share (EPS) for the quarter. The medical device company had revenue of $1.32 million for the quarter. NeuroMetrix had a negative trailing twelve-month return on equity of 31.31% and a negative net margin of 110.64%.

When did NeuroMetrix's stock split?

NeuroMetrix's stock reverse split on Wednesday, November 22nd 2023. The 1-8 reverse split was announced on Monday, November 20th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

What is Shai N. Gozani's approval rating as NeuroMetrix's CEO?

10 employees have rated NeuroMetrix Chief Executive Officer Shai N. Gozani on Glassdoor.com . Shai N. Gozani has an approval rating of 57% among the company's employees. This puts Shai N. Gozani in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of NeuroMetrix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroMetrix investors own include Merit Medical Systems (MMSI) , Palatin Technologies (PTN) , Citigroup (C) , Salesforce (CRM) , Nokia Oyj (NOK) , ReWalk Robotics (RWLK) , Advanced Micro Devices (AMD) and Vaxart (VXRT) .

How do I buy shares of NeuroMetrix?

Shares of NURO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NURO

NeuroMetrix (NURO) Stock Price, News & Analysis

→ Your Next Portfolio Star: Revealing 2024's Top Stock Pick (From Darwin) (Ad)

Free NURO Stock Alerts

$4.23

+0.58 (+15.89%)

(As of 01:56 PM ET)

Compare

Today's Range: $3.92
▼
$4.45
50-Day Range: $2.94
▼
$4.27
52-Week Range: $2.70
▼
$11.82

Volume: 165,612 shs
Average Volume: 42,246 shs
Market Capitalization: $8.42 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get NeuroMetrix alerts:

Ad DTI

Here’s how to start a “Weekend Side Hustle” from your sofa

Here’s how you can start your very own “Weekend Side Hustle” right from the comfort of your sofa! It doesn't matter if you have a multi-million dollar retirement account… Or if you’re just starting out with a few thousand.

Weekend after weekend!

About NeuroMetrix Stock (NASDAQ:NURO)

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

NURO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NURO Stock News Headlines

April 19, 2024 | finanznachrichten.de

NeuroMetrix, Inc.: NeuroMetrix Announces Steps Taken to Enhance Shareholder Value

April 19, 2024 | globenewswire.com

NeuroMetrix Announces Steps Taken to Enhance Shareholder Value

April 19, 2024 | Darwin (Ad)

2024's Must-Have Guide: Master Crypto Investment Today

The cryptocurrency revolution is here with Bitcoin soaring past the $70,000 milestone—a clear indicator of the booming digital currency market. Are you prepared to navigate these exciting yet complex waters? Introducing "Navigating the Future: A Comprehensive Guide to Cryptocurrency Investments in 2024." This free digital guide is your essential resource for understanding and capitalizing on cryptocurrency investments, tailored for both newcomers and seasoned investors. (**By clicking the link you are subscribing to The Conservative Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

April 18, 2024 | americanbankingnews.com

NeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.com

April 10, 2024 | americanbankingnews.com

NeuroMetrix (NASDAQ:NURO) Receives New Coverage from Analysts at StockNews.com

March 14, 2024 | globenewswire.com

NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy

March 13, 2024 | finanznachrichten.de

NeuroMetrix, Inc.: NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell Fibromyalgia

March 13, 2024 | globenewswire.com

NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia

April 19, 2024 | Darwin (Ad)

2024's Must-Have Guide: Master Crypto Investment Today

March 8, 2024 | finanznachrichten.de

RS Fund Management LLC: RS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc.

March 8, 2024 | finance.yahoo.com

RS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc.

February 25, 2024 | au.lifestyle.yahoo.com

Google releases new open LLMs, Rivian lays off staff and Signal rolls out usernames

February 24, 2024 | finance.yahoo.com

NeuroMetrix Full Year 2023 Earnings: US$6.08 loss per share (vs US$4.96 loss in FY 2022)

February 23, 2024 | finance.yahoo.com

NeuroMetrix, Inc. (NASDAQ:NURO) Q4 2023 Earnings Call Transcript

February 22, 2024 | finanznachrichten.de

NeuroMetrix, Inc.: NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights

February 22, 2024 | finance.yahoo.com

NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights

February 22, 2024 | globenewswire.com

NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights

February 15, 2024 | finance.yahoo.com

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call

February 15, 2024 | globenewswire.com

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call

February 13, 2024 | finanznachrichten.de

NeuroMetrix, Inc.: NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value

February 13, 2024 | markets.businessinsider.com

NeuroMetrix Plans Strategic Options To Promote Growth, Maximize Shareholder Value; Stock Drops

February 13, 2024 | finance.yahoo.com

NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value

January 8, 2024 | finance.yahoo.com

NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024

December 12, 2023 | finanznachrichten.de

NeuroMetrix, Inc.: NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell in Post-Acute COVID-19 Syndrome (Long COVID)

December 12, 2023 | finance.yahoo.com

NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)

December 5, 2023 | finance.yahoo.com

NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)

November 30, 2023 | msn.com

OPEN, AMPE and NURO are among pre market gainers

See More Headlines

Receive NURO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroMetrix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/22/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:NURO
CUSIP: N/A
CIK: 1289850
Web: www.neurometrix.com
Phone: (781) 890-9989
Fax: 302-636-5454
Employees: 26
Year Founded: 1996

Profitability

EPS (Most Recent Fiscal Year): ($6.23)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-6,530,000.00
Net Margins: -110.64%
Pretax Margin: -110.64%
Return on Equity: -31.31%
Return on Assets: -29.32%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 16.80
Quick Ratio: 15.55

Sales & Book Value

Annual Sales: $5.90 million
Price / Sales: 1.23
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $13.18 per share
Price / Book: 0.28

Miscellaneous

Outstanding Shares: 1,987,000
Free Float: 1,842,000
Market Cap: $7.25 million
Optionable: Not Optionable
Beta: 2.26

Social Links

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Dr. Shai N. Gozani M.D. (Age 59)
Ph.D., Founder, Chairman, CEO, President & Secretary
Comp: $437.82k
Mr. Thomas T. Higgins (Age 72)
Senior VP, CFO & Treasurer
Comp: $342.87k
Dr. Xuan Kong Ph.D.
Chief Data Scientist
Ms. Susan M. Bell R.N.
Senior Vice President of Population Health & Value Based Care

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

NURO Stock Analysis - Frequently Asked Questions

How have NURO shares performed in 2024?: NeuroMetrix's stock was trading at $3.60 at the beginning of the year. Since then, NURO stock has increased by 16.4% and is now trading at $4.19.
View the best growth stocks for 2024 here.
Are investors shorting NeuroMetrix?: NeuroMetrix saw a decrease in short interest in March. As of March 31st, there was short interest totaling 11,300 shares, a decrease of 51.3% from the March 15th total of 23,200 shares. Based on an average daily trading volume, of 44,800 shares, the short-interest ratio is currently 0.3 days. Approximately 0.8% of the shares of the stock are sold short.
View NeuroMetrix's Short Interest.
When is NeuroMetrix's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our NURO earnings forecast.
How were NeuroMetrix's earnings last quarter?: NeuroMetrix, Inc. (NASDAQ:NURO) announced its quarterly earnings results on Thursday, February, 22nd. The medical device company reported ($1.43) earnings per share (EPS) for the quarter. The medical device company had revenue of $1.32 million for the quarter. NeuroMetrix had a negative trailing twelve-month return on equity of 31.31% and a negative net margin of 110.64%.

When did NeuroMetrix's stock split?: NeuroMetrix's stock reverse split on Wednesday, November 22nd 2023. The 1-8 reverse split was announced on Monday, November 20th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.
What is Shai N. Gozani's approval rating as NeuroMetrix's CEO?: 10 employees have rated NeuroMetrix Chief Executive Officer Shai N. Gozani on Glassdoor.com. Shai N. Gozani has an approval rating of 57% among the company's employees. This puts Shai N. Gozani in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of NeuroMetrix own?: Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroMetrix investors own include Merit Medical Systems (MMSI), Palatin Technologies (PTN), Citigroup (C), Salesforce (CRM), Nokia Oyj (NOK), ReWalk Robotics (RWLK), Advanced Micro Devices (AMD) and Vaxart (VXRT).
How do I buy shares of NeuroMetrix?: Shares of NURO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NURO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial